Madrid, 7th February, 2008.- Cellerix, a product-focused biopharmaceutical company developing innovative medicines based on cell therapy, has appointed Jacques Theurillat as new member of its Board of Directors.

Jacques Theurillat has been AlbeaPharma AG’s Chief Executive Officer and President since March of 2007. Previously, he worked at Serono Group as strategic corporate development manager. In addition, he was a member of the Board of Directors and the Executive Committee.

Eduardo Bravo, CEO of Cellerix, said “We are delighted with Jacques Theurillat joining our team. His wide experience in this sector will be extremely useful, especially at this moment, as we face a very important stage in Cellerix and we are close to marketing our lead product, Cx401 ".

Born in 1959 in Switzerland, Jacques Theurillat has a degree in Law from the universities of Geneva and Madrid and also has financial and business management studies from Harvard Business School and Amsterdam Institute of Finance.

Notes to editors

Cellerix is a product-focused biopharmaceutical company developing innovative medicines based on cell therapy. The company has two products undergoing clinical trials: Cx401 for the treatment of perianal fistulas, currently in Phase III, and Cx501 for skin regeneration, currently in Phase II. Cx401 and Cx501 have orphan status by the European Medicines Agency (EMEA). Cellerix closed in September 2007 a €27.2 million financing round led by international venture capital companies. In October 2007 it entered into an exclusive license and development agreement with Axcan Pharma for the North American rights to Cx401